Recent meetings
No recorded meetings with EU commissioners.
Mission & Goals
Vaccine Formulation Institute (VFI) was established with initial funding from the European Commission (TRANSVAC) and with the support of the World Health Organization in 2012 and has since been dedicated to the development of vaccine adjuvants and the provision of formulation expertise to the entire vaccine community. VFI’s mission is to provide clinically-relevant adjuvants and expertise in vaccine formulation under “open-access” and affordable terms to the vaccine community, in order to accelerate the development of vaccines of Global Health importance.
EU Legislative Interests
Health Emergency Preparedness and Response Authority (HERA)
Communication Activities
Technical meeting planned in February 2026 with Christian Wimmer (HERA) to discuss possible interaction in the vaccine adjuvant field and involvement of VFI to support HERA activities. VFI has been acting/serving as the adjuvant platform for multiple EC-funded projects (FP7, Horizon 2020, Horizon Europe, etc) since its creation.
Interests Represented
Does not represent commercial interests
Member Of
VFI is sponsor of the DCVMN (Developing Countries Vaccine Manufacturers Network) - https://dcvmn.org/sponsors/
Organisation Members
VFI is a subsidiary of Vaccine Formulation Group SA, 4 Rue du Champ-Blanchod, 1228 Plan-les-Ouates
Additional Information
NB 1: EU programs of the current fiscal year - VFI is actively participating in 4 programs - however, the funding is covered by the Swiss government SERI. We indicated "1EUR" to be able to still mention our active participation. NB 2: total budget for the closed financial year 2024 - our understanding is that you are asking for the net profit, which we have put into the cell (=income from grants and other sources - (minus) expenditures).